The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. Issue 11 (November 2015)

• Record Type: Journal Article
• Authors: Wu, Qiong; Madany, Pasil; Akech, Jacqueline; Dobson, Jason R.; Douthwright, Stephen; Browne, Gillian; Colby, Jennifer L.; Winter, Georg E.; Bradner, James E.; Pratap, Jitesh; Sluder, Greenfield; Bhargava, Rohit; Chiosea, Simion I.; van Wijnen, Andre J.; Stein, Janet L.; Stein, Gary S.; Lian, Jane B.; Nickerson, Jeffrey A.; Imbalzano, Anthony N.
• Is Part Of: Journal of cellular physiology. Volume 230:Issue 11(2015:Nov.)
• Page Start: 2683
• Page End: 2694
• Publication Date: 2015-11
• Subjects: Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.24991
• Languages: English
• ISSNs: 0021-9541

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jcp24991-sec-0001" sec-type="section"> <p>The Brahma (BRM) and Brahma‐related Gene 1 (BRG1) ATPases are highly conserved homologs that catalyze the chromatin remodeling functions of the multi‐subunit human SWI/SNF chromatin remodeling enzymes in a mutually exclusive manner. SWI/SNF enzyme subunits are mutated or missing in many cancer types, but are overexpressed without apparent mutation in other cancers. Here, we report that both BRG1 and BRM are overexpressed in most primary breast cancers independent of the tumor's receptor status. Knockdown of either ATPase in a triple negative breast cancer cell line reduced tumor formation in vivo and cell proliferation in vitro. Fewer cells in S phase and an extended cell cycle progression time were observed without any indication of apoptosis, senescence, or alterations in migration or attachment properties. Combined knockdown of BRM and BRG1 showed additive effects in the reduction of cell proliferation and time required for completion of cell cycle, suggesting that these enzymes promote cell cycle progression through independent mechanisms. Knockout of BRG1 or BRM using CRISPR/Cas9 technology resulted in the loss of viability, consistent with a requirement for both enzymes in triple negative breast cancer cells. J. Cell. Physiol. 9999: 2683–2694, 2015. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>